KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Payables: 2010-2024

Historic Payables for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $11.6 million.

  • Nektar Therapeutics' Payables rose 81.45% to $15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.2 million, marking a year-over-year increase of 76.00%. This contributed to the annual value of $11.6 million for FY2024, which is 17.38% up from last year.
  • Nektar Therapeutics' Payables amounted to $11.6 million in FY2024, which was up 17.38% from $9.8 million recorded in FY2023.
  • In the past 5 years, Nektar Therapeutics' Payables registered a high of $22.1 million during FY2020, and its lowest value of $9.7 million during FY2021.
  • Moreover, its 3-year median value for Payables was $11.6 million (2024), whereas its average is $11.5 million.
  • Per our database at Business Quant, Nektar Therapeutics' Payables slumped by 55.97% in 2021 and then spiked by 33.17% in 2022.
  • Over the past 5 years, Nektar Therapeutics' Payables (Yearly) stood at $22.1 million in 2020, then plummeted by 55.97% to $9.7 million in 2021, then skyrocketed by 33.17% to $13.0 million in 2022, then dropped by 24.13% to $9.8 million in 2023, then grew by 17.38% to $11.6 million in 2024.